Oxatomide: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Protected "Oxatomide": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
No edit summary
 
(One intermediate revision by the same user not shown)
Line 1: Line 1:
{{drugbox |
{{Drugbox
| IUPAC_name =  
| Verifiedfields = changed
| image = Oxatomide.png  
| verifiedrevid = 462266871
| IUPAC_name = 1-{3-[4-(diphenylmethyl)piperazin-1-yl]propyl}-1,3-dihydro-2''H''-benzimidazol-2-one
| image = Oxatomide.png
 
<!--Clinical data-->
| tradename = Tinset, Cedlips, Atoxan
| Drugs.com = {{drugs.com|international|oxatomide}}
| pregnancy_category = 
| legal_status = Rx-only
| routes_of_administration = Oral
 
<!--Pharmacokinetic data-->
| bioavailability = 
| metabolism = 
| elimination_half-life = 
| excretion = 
 
<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 60607-34-3
| CAS_number = 60607-34-3
| ATC_prefix = R06
| ATC_prefix = R06
| ATC_suffix = AE06
| ATC_suffix = AE06
| PubChem = 615
| PubChem = 4615
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4454
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = J31IL9Z2EE
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01773
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 13828
 
<!--Chemical data-->
| C=27 | H=30 | N=4 | O=1  
| C=27 | H=30 | N=4 | O=1  
| molecular_weight = 426.553 g/mol
| molecular_weight = 426.553 g/mol
| bioavailability =  
| smiles = O=C2Nc1ccccc1N2CCCN5CCN(C(c3ccccc3)c4ccccc4)CC5
| protein_bound =  
| InChI = 1/C27H30N4O/c32-27-28-24-14-7-8-15-25(24)31(27)17-9-16-29-18-20-30(21-19-29)26(22-10-3-1-4-11-22)23-12-5-2-6-13-23/h1-8,10-15,26H,9,16-21H2,(H,28,32)
| metabolism =  
| InChIKey = BAINIUMDFURPJM-UHFFFAOYAU
| elimination_half-life =  
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| excretion =
| StdInChI = 1S/C27H30N4O/c32-27-28-24-14-7-8-15-25(24)31(27)17-9-16-29-18-20-30(21-19-29)26(22-10-3-1-4-11-22)23-12-5-2-6-13-23/h1-8,10-15,26H,9,16-21H2,(H,28,32)
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| pregnancy_US =  <!-- A / B            / C / D / X -->
| StdInChIKey = BAINIUMDFURPJM-UHFFFAOYSA-N
| pregnancy_category = 
| legal_AU =      <!-- Unscheduled / S2 / S3 / S4  / S8 -->
| legal_UK =      <!-- GSL        / P      / POM / CD -->
| legal_US =      <!-- OTC                  / Rx-only  -->
| legal_status =  
| routes_of_administration =  
}}
}}
'''Oxatomide''' is a [[piperazine]] [[antihistamine]]. It was discovered at [[Janssen Pharmaceutica]] in [[1975]].
              __NOTOC__
{{SI}}
{{CMG}}
 
==Overview==
   
'''Oxatomide''' (R35443) is a [[first-generation antihistamine]] of the [[phenylpiperazine]] class.<ref name="pmid6138301">{{cite journal | author = Ohmori K, Ishii H, Nito M, Shuto K, Nakamizo N | title = [Pharmacological studies on oxatomide (KW-4354). (7) Antagonistic effects on chemical mediators] | language = Japanese | journal = Nippon Yakurigaku Zasshi. Folia Pharmacologica Japonica | volume = 81 | issue = 5 | pages = 399–409 |date=May 1983 | pmid = 6138301 | doi = 10.1254/fpj.81.399| url = }}</ref> It was discovered at [[Janssen Pharmaceutica]] in 1975. Oxatomide lacks any [[anticholinergic]] effects.<ref name="pmid6138301">{{cite journal | author = Ohmori K, Ishii H, Nito M, Shuto K, Nakamizo N | title = [Pharmacological studies on oxatomide (KW-4354). (7) Antagonistic effects on chemical mediators] | language = Japanese | journal = Nippon Yakurigaku Zasshi. Folia Pharmacologica Japonica | volume = 81 | issue = 5 | pages = 399–409 |date=May 1983 | pmid = 6138301 | doi = 10.1254/fpj.81.399| url = }}</ref> In addition to its [[H1 receptor|H<sub>1</sub> receptor]] [[receptor_antagonist|antagonism]], it also possesses [[antiserotonergic]] actions.<ref name="pmid6138301">{{cite journal | author = Ohmori K, Ishii H, Nito M, Shuto K, Nakamizo N | title = [Pharmacological studies on oxatomide (KW-4354). (7) Antagonistic effects on chemical mediators] | language = Japanese | journal = Nippon Yakurigaku Zasshi. Folia Pharmacologica Japonica | volume = 81 | issue = 5 | pages = 399–409 |date=May 1983 | pmid = 6138301 | doi = 10.1254/fpj.81.399| url = }}</ref>
 
==See also==
*[[Piperazine]]
 
==References==
{{Reflist|2}}


{{Antihistamines}}
{{Antihistamines}}




{{drug-stub}}
[[th:ออกซาโทไมด์]]
[[Category:H1 receptor antagonists]]
[[Category:H1 receptor antagonists]]
[[Category:Piperazines]]
[[Category:Piperazines]]
{{WikiDoc Help Menu}}
[[Category:Benzimidazoles]]
{{WikiDoc Sources}}
[[Category:Ureas]]
[[Category:Lactams]]
[[Category:Drug]]

Latest revision as of 15:28, 10 April 2015

Oxatomide
Clinical data
Trade namesTinset, Cedlips, Atoxan
AHFS/Drugs.comInternational Drug Names
Routes of
administration		Oral
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC27H30N4O
Molar mass426.553 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Oxatomide

Articles

Most recent articles on Oxatomide

Most cited articles on Oxatomide

Review articles on Oxatomide

Articles on Oxatomide in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Oxatomide

Images of Oxatomide

Photos of Oxatomide

Podcasts & MP3s on Oxatomide

Videos on Oxatomide

Evidence Based Medicine

Cochrane Collaboration on Oxatomide

Bandolier on Oxatomide

TRIP on Oxatomide

Clinical Trials

Ongoing Trials on Oxatomide at Clinical Trials.gov

Trial results on Oxatomide

Clinical Trials on Oxatomide at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Oxatomide

NICE Guidance on Oxatomide

NHS PRODIGY Guidance

FDA on Oxatomide

CDC on Oxatomide

Books

Books on Oxatomide

News

Oxatomide in the news

Be alerted to news on Oxatomide

News trends on Oxatomide

Commentary

Blogs on Oxatomide

Definitions

Definitions of Oxatomide

Patient Resources / Community

Patient resources on Oxatomide

Discussion groups on Oxatomide

Patient Handouts on Oxatomide

Directions to Hospitals Treating Oxatomide

Risk calculators and risk factors for Oxatomide

Healthcare Provider Resources

Symptoms of Oxatomide

Causes & Risk Factors for Oxatomide

Diagnostic studies for Oxatomide

Treatment of Oxatomide

Continuing Medical Education (CME)

CME Programs on Oxatomide

International

Oxatomide en Espanol

Oxatomide en Francais

Business

Oxatomide in the Marketplace

Patents on Oxatomide

Experimental / Informatics

List of terms related to Oxatomide

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Oxatomide (R35443) is a first-generation antihistamine of the phenylpiperazine class.[1] It was discovered at Janssen Pharmaceutica in 1975. Oxatomide lacks any anticholinergic effects.[1] In addition to its H1 receptor antagonism, it also possesses antiserotonergic actions.[1]

See also

References

  1. ↑ 1.0 1.1 1.2 Ohmori K, Ishii H, Nito M, Shuto K, Nakamizo N (May 1983). "[Pharmacological studies on oxatomide (KW-4354). (7) Antagonistic effects on chemical mediators]". Nippon Yakurigaku Zasshi. Folia Pharmacologica Japonica (in Japanese). 81 (5): 399–409. doi:10.1254/fpj.81.399. PMID 6138301.
Retrieved from "https://www.wikidoc.org/index.php?title=Oxatomide&oldid=1085960"